E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
GIST and mCRC patients |
GIST en mCRC patienten |
|
E.1.1.1 | Medical condition in easily understood language |
Gastro-intestinal stromal tumour patients and metastatic colorectal carcinoma patients |
Gastro-intestinale stromale tumoren patienten en gemetastaseerd colorectal carcinoom patienten |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the area under the curve (AUC) of regorafenib compared to regorafenib concomitantly used with esomeprazole and to regorafenib used with esomeprazole 3 hours prior in patients with mCRC or GIST. |
Het bepalen van de invloed van esomeprazol op de AUC van regorafenib bij gelijktijdig gebruik en bij 3 uur eerder inname van de esomeprazol bij patienten met gemetastaseerd CRC of GIST |
|
E.2.2 | Secondary objectives of the trial |
1. Other pharmacokinetic outcomes (i.e. clearance, maximum concentration (Cmax) and time to Cmax (tmax)).
2. To evaluate the incidence and severity of side-effects of treatment with regorafenib in absence and presence of esomeprazole |
1.Andere pharmacokinetische uitkomsten (zoals klaring, de maximale concentratie (Cmax) en de tijd tot Cmax (tmax).
2.Het evalueren van de incidentie en ernst van de bijwerkingen van een behandeling met regorafenib in de aan- en afwezigheid van esomeprazole |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age ≥ 18 years
2. Histological or cytological confirmed diagnosis of mCRC or GIST
3. ECOG Performance Status ≤ 1
4. Signed Informed Consent Form prior to screening evaluations
5. No concurrent (over the counter) use of other acid reducing drugs, other than esomeprazole 40mg (PPIs, H2As and/or antacids) once daily during the study.
6. No concurrent medication or supplements which can interact with esomeprazole or regorafenib during the study period.
7. Abstain from grapefruit, grapefruit juice, herbal dietary supplements, and herbal tea during the study period.
8. Adequate baseline patient characteristics |
1. Leeftijd ≥ 18 jaar
2. Histologisch of cytologisch bevestigde diagnose van mCRC of GIST
3. ECOG Performance Status ≤ 1
4. Getekend Informed Consent Form voor de screening
5. Geen gebruik van andere zuurremmende medicatie anders dan esomeprazole 40mg
6. Geen gebruik van medicatie of supplementen die een interactie kunnen hebben met esomeprazole of regorafenib
7. Geen gebruik van grapefruit, grapefruit sap, kruiden supplementen of kruidenthee
8. Adequate baseline karakteristieken |
|
E.4 | Principal exclusion criteria |
1. Pregnant or lactating patients.
2. Patients with known impaired drug absorption (e.g. gastrectomy and achlorhydria).
3. Known serious illness or medical unstable conditions that could interfere with this study
4. Patients with evidence or history of any bleeding diathesis, irrespective of severity
5. Cardiac history ( recent myocardial infarction, unstable or new-onset angina, uncontrolled cardiac arrhythmias)
6. Uwillingness to abstain from grapefruit (juice), (herbal) dietary supplements, herbals, over-the-counter medication (except for paracetamol and ibuprofen) and other drugs known to seriously interact with esomeprazole and regorafenib during the study period.
7. Unwillingness to abstain from acid beverages such as jus d’orange and other acidic beverages in the morning during regorafenib treatment in this study.
8. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation.
9. Symptomatic CNS metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent. |
1. Zwanger of het geven van borstvoeding
2. Patienten met een bekende verminderde absorptive van medicatie
3. Bekende ernstige ziekte of medisch instabiele conditie die kan interfereren met de studie
4. Patienten met een geschiedenis van bloedingsneiging
5. Cardiale voorgeschiedenis (recent myocardinfarct, onstabiele of recent ontstane angina, ongecontroleerde ritmestoornissen)
6. Niet bereid om te stoppen met grapefruit (sap), kruidensupplementen, kuiden, zelhulpmedicatie (behalve paracetamol en ibuprofen) en andere medicatie die interactie kan hebben met esomeprazol en regorafenib.
7. Niet bereid om te stoppen met zure dranken zoals jus d’orange in de ochtend tijdens de behandeling met regorafenib.
8. Overgevoeligheid voor een van de studie medicijnen of bestandelen ervan
9. Symptomatische CZS metastases of voorgeschiedenis van psychiatrische ziekte die een goede informed consent procedure verhindert. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate the area under the curve (AUC) of regorafenib compared to regorafenib concomitantly used with esomeprazole and to regorafenib used with esomeprazole 3 hours prior in patients with mCRC or GIST. |
Het bepalen van de invloed van esomeprazol op de AUC van regorafenib bij gelijktijdig gebruik en bij 3 uur eerder inname van de esomeprazol bij patienten met gemetastaseerd CRC of GIST |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
End of study |
Einde van de studie |
|
E.5.2 | Secondary end point(s) |
1. Other pharmacokinetic outcomes (i.e. clearance, maximum concentration (Cmax) and time to Cmax (tmax)).
2. To evaluate the incidence and severity of side-effects of treatment with regorafenib in absence and presence of esomeprazole |
1.Andere pharmacokinetische uitkomsten (zoals klaring, de maximale concentratie (Cmax) en de tijd tot Cmax (tmax).
2.Het evalueren van de incidentie en ernst van de bijwerkingen van een behandeling met regorafenib in de aan- en afwezigheid van esomeprazole |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
End of study |
Einde van de studie |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Cross-over design, elke patient is zijn eigen controle |
Cross-over design, each patient is his own control |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Laatste bezoek van laatste studiepatient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |